<DOC>
	<DOCNO>NCT02606045</DOCNO>
	<brief_summary>This outpatient , 24-week Phase III prospective , randomize , crossover trial compare recombinant von Willebrand factor ( rVWF ) tranexamic acid ( TA , LystedaÂ® ) minimize menorrhagia woman type 1 von Willebrand disease ( VWD ) . The purpose Phase III multicenter prospective , randomize , crossover arm trial compare recombinant von Willebrand factor ( rVWF ) tranexamic acid ( TA ) reduce severity menorrhagia woman von Willebrand disease .</brief_summary>
	<brief_title>Minimize Menorrhagia Women With Type 1 Von Willebrand Disease</brief_title>
	<detailed_description>In study , woman age 18-45 year mild moderate VWD menorrhagia enrol hemophilia treatment center ( HTCs ) provide information menstrual bleeding two past monthly cycle establish baseline bleeding frequency . Only woman regular menses , define menses every 21-35 day enrol . A total 60 subject recruit enrol 16 HTC site . Following enrollment , subject randomize Group I Group II first five day next four consecutive menstrual cycle . Those randomized Group I treat Arm A menstrual bleeding cycle 1 2 , follow Arm B menstrual bleeding cycle 3 4 . Those randomize Group II treat Arm B menstrual bleeding cycle 1 2 , follow Arm A menstrual bleeding cycle 3 4 . Subjects randomize Group I receive Arm A rVWF 40 IU/kg intravenously ( IV ) infusion day 1 two menstrual cycle , Cycles 1 2 . They cross Arm B , TA 650 mg 2 tablet orally ( po ) three time daily day 1-5 two menstrual cycle , Cycles 3 4 . Subjects randomize Group II receive Arm B , TA 650 mg 2 tablet orally ( po ) three time daily day 1-5 , two menstrual cycle , Cycles 1 2 . They cross Arm A , rVWF 40 IU/kg intravenously ( IV ) infusion day 1 two menstrual cycle , Cycles 3 4 . This regimen may give HTC clinic home visiting nurse . Baseline laboratory study draw screen , include Blood Counts : hemoglobin , white count , differential , platelet ; Iron Tests : iron , total iron binding capacity ( TIBC ) , ferritin ; Thyroid Test : thyroid stimulate hormone ( TSH ) ; Von Willebrand Tests ( VWF relate test ) . Before initiate treatment , subject train HTC nurse 1 ) reading urine pregnancy test 2 ) completion pictorial blood assessment chart ( PBAC ) , cycle severity score ( CSR ) , cycle length ( CL ) ; 3 ) completion patient diary . Following randomization , subject administer home pregnancy test prior first 5-day dosing cycle . On four dosing cycle , Cycles 1-4 , PBAC , CSR , CL record daily . After completion study drug cycle 2 , Crossover Study Visit occur , subject give new supply study drug study arm cross ; subject diary return coagulation study quality life questionnaire perform . At 10-14 day completion study drug Cycle 4 , End Study Visit occur , subject diary return quality life questionnaire perform . All study visit within +/- 2 day schedule visit . Study visit every 2 month , end cycle 2 ( cross-over ) end cycle 4 ( end study ) treatment diary review bleeding frequency , side effect , medication . Menstrual bleeding PBAC , cycle severity , cycle duration , health-related quality-of-life ( HRQoL ) questionnaire , include Rand Short Form 36-Question Health Survey ( SF-36 ) , Ruta Menorrhagia Severity Scale , Center Disease Control Health-Related Quality Life-14 Question Form ( CDC-HRQoL14 ) , Center Epidemiologic Studies Depression Scale ( CES-D ) assess baseline cycle 2 cycle 4 . The study innovative 1 ) evaluation recombinant VWF , new high purity recombinant VWF protein , reduce menorrhagia , compare current non-hormonal standard , tranexamic acid ( TA ) ; 2 ) investigation relationship VWF menstrual bleeding PBAC score , assess VWD parameter : VWF ristocetin co-factor ( VWF : RCo ) , VWF antigen ( VWF : Ag ) , FVIII : C , VWF multimers , include high molecular weight multimers ( HMW ) electrophoresis , VWF genotype ; 3 ) use `` home treatment injection '' VWD ; 4 ) comparison two quality life measure assess treatment response study arm , one specific bleed disorder one specific menstrual disorder .</detailed_description>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Von Willebrand Disease , Type 1</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>1 . Adult females1845 year age . 2 . Mild moderate von Willebrand disease ( VWF : RCo &lt; 0.50 U/ml , normal multimers , past bleeding ) 3 . Menorrhagia define PBAC &gt; 100 least one last two menstrual cycle . 4 . Regular menses , least every 2135 day . 5 . Willingness blood draw 6 . No prior history allergic reaction anaphylaxis rVWF TA . 7 . Willingness avoid aspirin ( ASA ) nonsteroidal antiinflammatory agent ( NSAIDS ) study . 8 . Willingness comply randomization rVWF TA study arm . 9 . Willingness keep personal diary menorrhagia bleed frequency duration severity pictorial blood assessment chart , drug hemostatic agent take . 10 . Willingness make 4 visit undergo blood sample coagulation study , accept randomization two therapy four consecutive menstrual cycle , include endofstudy visit . 1 . Age le 18 year . 2 . Any bleed disorder von Willebrand disease ; past thrombotic disease 3 . Pregnant lactating , use hormone oral contraceptive norplant past 3 month 4 . Platelet count &lt; 100,000/ul . 5 . Past allergic reaction rVWF TA . 6 . Use immunomodulatory experimental drug . 7 . Surgery within past 8 week . 8 . Concomitant use antiplatelet drug , anticoagulant , dextran , aspirin NSAIDs . 9 . Treatment DDAVP , cryoprecipitate , whole blood , plasma plasma derivative contain VWF within 5 day study . 10 . Inability comply study requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>menorrhagia</keyword>
	<keyword>VWD</keyword>
</DOC>